Tube Racks
Abcam DNQ x , AMPA / kainate antagonist, 50MG
MW 252.14 Da, Purity >99%. AMPA / kainate antagonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam PPADS, P2 purinergic receptor antagonist, 10MG
MW 599.3 Da. PPADS, P2 purinergic receptor antagonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Cromakalim, KIR6. x (KATP) channel activator, 10MG
MW 286.33 g/mol, Purity >99%. KIR6.x (KATP) channel activator. Orally active, potent smooth muscle relaxant.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Esomeprazole sodium, H+/ K+-ATPase (proton pump) inhibitor, 250MG
MW 367.4 Da, Purity >99%. H+ / K+-ATPase (proton pump) inhibitor (IC50 = 2.3 µM). *S*-enantiomer of omeprazole. Attenuates intestinal mucosal barrier damage and can promote healing of gastric lesions in rats. Also inhibits Cytochrome P450 2C19 (CYP2C9), CYP2C19 and CYP3A4 (Ki values are 81.5, 8.6 and 46.6 µM, respectively).
The product is subject to the following: Abcam Restricted Use Statement
Abcam NKH 477 (Colforsin daropate), an adenylyl cyclase activator, 10MG
MW 546.1 Da. Water-soluble adenylyl cyclase activator. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ML-SA1, TRPML agonist, 50MG
MW 362.4 Da, Purity >98%. Selective TRPML agonist. Induces TRPML1, 2 and 3-mediated Ca²+ release from lysosomes in vitro. Does not activate TRPM2, TRPV2, TRPA1, TRPV3, TRPC6 channels. Cell-permeable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam (R,S)-AMPA, AMPA agonist, 50MG
MW 186.17 Da, Purity >99%. Prototypic agonist for AMPA receptors. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Quercetin, Antio x idative flavonoid, 100MG
MW 302.23 Da, Purity >97%. Antioxidative flavonoid. Anticancer, antithrombotic and anti-inflammatory agent. Actions include inhibition of mitochondrial ATPase, phosphodiesterases, PI3-kinase and PIP kinase activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Cyclothiazide, AMPA receptor desensitisation inhibitor, 10MG
MW 389.9 Da, Purity >98%. Positive allosteric modulator of AMPA receptors. Produces a fast inhibition of AMPA receptor desensitization and a much slower potentiation of the AMPA current. Also available in Kit: Ionotropic agonists (ab120323).
The product is subject to the following: Abcam Restricted Use Statement
Abcam CNQ x , AMPA / kainate antagonist, 10MG
MW 232.15 Da, Purity >99%. Potent, competitive AMPA / kainate receptor antagonist. Also antagonist at NMDA receptor glycine site.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CAY10602, SIRT1 Activator, 100MG
MW 418.4 Da, Purity >95%. SIRT1 Activator. Suppresses NF-κB-dependent induction of TNF-α by LPS (IC₇₀ = 60 μM, THP-1 cells). Upregulates PPARδ-mediated transcription in ECs.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ranolazine dihydrochloride, Anti-ischemic agent, 100MG
MW 500.5 Da, Purity >99%. Novel metabolic modulator and membrane stabilizer. Partial fatty acid oxidation inhibitor. Pyruvate dehydrogenase activator. Shifts myocardial energy metabolism towards glucose for ATP production. Inhibits late INa and IKr currents. Anti-ischemic effects in vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam U-51605, PGI2 and T x A2 synthase inhibitor, 100UG
MW 332.49 g/mol, Purity >98%. Selective inhibitor of PGI₂ synthase (IC₅₀ = 2 μM) and TXA₂ synthase. PGH₂ analog. Partial agonist at TP receptors.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GANT 61, GLI1 and 2 inhibitor, 10MG
MW 429.61 g/mol, Purity >98%. Selective GLI1 and 2 inhibitor (IC₅₀ = 5 μM). Blocks the hedgehog/smoothened signaling pathway. Anticancer activity in vitro and in vivo.
The product is subject to the following: Abcam Restricted Use Statement